Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9164 · 1 trial · 1 indication
Maximum FEV1 value
Trough FEV1 value
| Arm | Type | Description |
|---|---|---|
| AZD9164 100 mcg First, then Placebo for Spririva | EXPERIMENTAL | 1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation |
| AZD9164 400 mcg First, then Placebo for Spiriva | EXPERIMENTAL | 1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation |
| AZD9164 1200 mcg First, then Placebo for Spiriva | EXPERIMENTAL | 1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation |
| Spiriva 18 mcg First, then Placebo for AZD9164 | ACTIVE_COMPARATOR | 1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride) |
| Placebo for Spiriva First, then Placebo for AZD9164 | PLACEBO_COMPARATOR | 1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride) |
| Name | Type | Description |
|---|---|---|
| AZD9164 | DRUG | Solution for inhalation through nebulization, single dose |
| Tiotropium | DRUG | Dry powder for inhalation, single dose |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * A clinical diagnosis of COPD * FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post- bronchodilator FEV1/FVC \< 70% Exclusion Criteria: * Any clinically relevant abnormal findings at screening examinations * Any clinically significant disease or disorde...
AZD9164 is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), a respiratory condition. It is an investigational small molecule and is not yet approved for any indication. AstraZeneca PLC is the developer.
AZD9164 targets CHRM3, the muscarinic acetylcholine receptor M3. It acts as an antagonist at this receptor. By blocking CHRM3, AZD9164 is designed to reduce cholinergic signaling in the airways, which may help alleviate COPD symptoms.
AstraZeneca PLC (ticker: AZN) is developing AZD9164. The company is responsible for the clinical development of this small molecule for COPD.
AZD9164 is in Phase 2 clinical development. It has not been approved by the FDA or any regulatory agency. The drug remains investigational for the treatment of Chronic Obstructive Pulmonary Disease.
AZD9164 has been studied in one completed Phase 2 trial, NCT00939211, titled 'The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease.' The trial enrolled 25 participants in Sweden and was randomized, double-blind, and placebo-controlled.